The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Anticholinergic drug use and risk for dementia: target for dementia prevention
Abstract
An increasing number of longitudinal cohort studies have identified a risk increase for dementia by the chronic use of drugs with anticholinergic properties. The respective data from the German Study on Aging, Cognition and Dementia in Primary Care Patients (AgeCoDe) also showing risk increase (hazard ratio = 2.081) are reported here. The mechanisms by which the risk increase is transported are still unknown. Irritation of compensated alterations of cholinergic transmission at the pre-dementia stage of Alzheimer's disease (AD) or acceleration of neuroinflammation by disturbance of the anti-inflammatory effect of cholinergic innervation are discussed. In terms of dementia prevention, centrally acting anticholinergic drugs should be strictly avoided, because of long-term dementia risk increase in addition to acute negative effects on cognition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Several investigators have reported that anticholinergic medications may be associated with increased risk for sustained cognitive deficits such as mild cognitive impairment or dementia.
“However, several investigators have reported that anticholinergic medications may be associated with increased risk for sustained cognitive deficits such as mild cognitive impairment or dementia.1,2,14”
From Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study (2015) · cites this paper as [1]
The study findings are consistent with two cohort studies that examined anticholinergic use and incident dementia risk.
“Our study findings are consistent with two cohort studies that have examined anticholinergic use and incident dementia risk.1,14”
From Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study (2015) · cites this paper as [1]
Prior observational studies of anticholinergic medications and dementia ascertained current anticholinergic use only at study entry and periodically during follow-up by conducting a medication inventory.
“First, current anticholinergic use was only ascertained at study entry and periodically during follow-up by conducting a medication inventory. 1,14”
From Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study (2015) · cites this paper as [1]
Another study conducted in Germany among primary care patients 75 years and older found that any anticholinergic use during the 54 month study period was associated with an increased risk for dementia (adjusted HR 2.0) compared to non-use.
“Another study conducted in Germany among primary care patients 75 years and older found that any anticholinergic use during the 54 month study period was associated with an increased risk for dementia (adjusted HR 2.0) compared to non-use.1”
From Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study (2015) · cites this paper as [1]
Citations
Cites
Tracey, K. J. (2002) · Nature · doi:10.1038/nature01321 · Cited by 3,728
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment
on behalf of the Rofecoxib Protocol 078 study group, Thal, L. J., Ferris, S. H., Kirby, L., Block, G. A., Lines, C. R., Yuen, E., Assaid, C., Nessly, M. L., Norman, B. A., et al. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300690 · Cited by 402
Flagged first, then by citations
Research works printed but not linked: 23
- Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L, Breitner JC, Cache County Study Investigators (2002) Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 59:880–886 · DOI
- Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57:1439–1443 · DOI
- Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM (2009) Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam study. J Neurol Neurosurg Psychiatry 80:13–17 · DOI · Paper page
- Peila R, White LR, Masaki K, Petrovitch H, Launer LJ (2006) Reducing the risk of dementia: efficacy of long-term treatment of hypertension. Stroke 37:1165–1170 · DOI · Paper page
- Shah K, Qureshi SU, Johnson M, Parikh N, Schulz PE, Kunik ME (2009) Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am J Geriatr Pharmacother 7:250–261 · DOI
- Egger SS, Bachmann A, Hubmann N, Schlienger RG, Krähenbühl S (2006) Prevalence of potentially inappropriate medication use in elderly patients: comparison between general medical and geriatric wards. Drugs Aging 23:823–837 · DOI
- Tune LE (2001) Anticholinergic effects of medication in elderly patients. J Clin Psychiatry 62:11–14
- Low LF, Anstey KJ, Sachdev P (2009) Use of medications with anticholinergic properties and cognitive function in a young-old community sample. Int J Geriatr Psychiatry 24:578–584 · DOI
- Ancelin ML, Artero S, Portet F, Dupuy AM, Touchon J, Ritchie K (2006) Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 332:455–459 · DOI · Paper page
- Carrière I, Fourrier-Reglat A, Dartigues JF, Rouaud O, Pasquier F, Ritchie K, Ancelin ML (2009) Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med 169:1317–1324 · DOI · Paper page
- Campbell NL, Boustani MA, Lane KA, Gao S, Hendrie H, Khan BA, Murrell JR, Unverzagt FW, Hake A, Smith-Gamble V, Hall K (2010) Use of anticholinergics and the risk of cognitive impairment in an African American population. Neurology 75:152–159 · DOI · Paper page
- Boustani MA, Campbell NL, Mungers S, Maidment I, Fox GC (2008) Impact of anticholinergics on the aging brain: a review and practical applications. Aging Health 4:311–320 · DOI · Paper page
- Jessen F, Wiese B, Bachmann C, Eifflaender-Gorfer S, Haller F, Kölsch H, Luck T, Mösch E, van den Bussche H, Wagner M, Wollny A, Zimmermann T, Pentzek M, Riedel-Heller SG, Romberg HP, Weyerer S, Kaduszkiewicz H, Maier W, Bickel H, German Study on Aging, Cognition and Dementia in Primary Care Patients Study Group (2010) Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment. Arch Gen Psychiatry 67:414–422 · DOI
- Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, Mahmoud RA, Kirshner MA, Sorisio DA, Bies RR, Gharabawi G (2008) Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 56:1333–1341 · DOI
- Gilles C, Luthringer R (2007) Pharmacological models in healthy volunteers: their use in the clinical development of psychotropic drugs. J Psychopharmacol 21:272–282 · DOI
- Mesulam M, Shaw P, Mash D, Weintraub S (2004) Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann Neurol 55:815–828 · DOI
- Grothe M, Zaborszky L, Atienza M, Gil-Neciga E, Rodriguez-Romero R, Teipel SJ, Amunts K, Suarez-Gonzalez A, Cantero JL (2010) Reduction of basal forebrain cholinergic system parallels cognitive impairment in patients at high risk of developing Alzheimer’s disease. Cereb Cortex 20:1685–1695 · DOI
- Muth K, Schönmeyer R, Matura S, Haenschel C, Schröder J, Pantel J (2010) Mild cognitive impairment in the elderly is associated with volume loss of the cholinergic basal forebrain region. Biol Psychiatry 67:588–591 · DOI
- Herholz K (2008) Acetylcholine esterase activity in mild cognitive impairment and Alzheimer’s disease. Eur J Nucl Med Mol Imaging 35:25–29 · DOI
- DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA, Cochran EJ, Kordower JH, Mufson EJ (2002) Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 51:145–155 · DOI · Paper page
- Ikonomovic MD, Abrahamson EE, Isanski BA, Wuu J, Mufson EJ, DeKosky ST (2007) Superior frontal cortex cholinergic axon density in mild cognitive impairment and early Alzheimer disease. Arch Neurol 64:1312–1317 · DOI
- De Simone R, Ajmone-Cat MA, Carnevale D, Minghetti L (2005) Activation of α7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures. J Neuroinflammation 2:4 · DOI
- van Gool WA, van de Beek D, Eikelenboom P (2010) Systemic infection and delirium: when cytokines and acetylcholine collide. Lancet 375:773–775 · DOI
Cited by
Sorted by citations
Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study
Gray, S. L., Anderson, M. L., Dublin, S., Hanlon, J. T., Hubbard, R., Walker, R., Yu, O., Crane, P. K., & Larson, E. B. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.7663 · Cited by 1,111
Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study
Coupland, C. A. C., Hill, T., Dening, T., Morriss, R., Moore, M., & Hippisley-Cox, J. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.0677 · Cited by 637
van Beers, M., Janssen, D. J. A., Gosker, H. R., & Schols, A. M. W. J. (2018) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2018.1533405 · Cited by 77
Exposure to Antidepressant Medication and the Risk of Incident Dementia
Kodesh, A., Sandin, S., Reichenberg, A., Rotstein, A., Pedersen, N. L., Ericsson, M., Karlsson, I. K., Davidson, M., & Levine, S. Z. (2019) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.05.019 · Cited by 63
Risk of dementia among antidepressant elderly users: A population-based cohort analysis in Spain
Santandreu, J., Caballero, F. F., Gómez-Serranillos, M. P., & González-Burgos, E. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.01.002 · Cited by 3
Metadata
- Authors
- Jessen, F., Kaduszkiewicz, H., Daerr, M., Bickel, H., Pentzek, M., Riedel-Heller, S., Wagner, M., Weyerer, S., Wiese, B., van den Bussche, H., Broich, K., & Maier, W.
- Affiliations
- University of Bonn (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Technical University of Munich (DE)
- Heinrich Heine University Düsseldorf (DE)
- Leipzig University (DE)
- Central Institute of Mental Health (DE)
- Medizinische Hochschule Hannover (DE)
- Federal Institute for Drugs and Medical Devices (DE)
- Corresponding author
- Jessen, Frank
- ORCID
- Venue
- European Archives of Psychiatry and Clinical Neuroscience
- Published
- 2010-10-20
- Volume
- 260
- Issue
- S2
- Pages
- 111-115
- ISSN
- 0003-9373 (ISSN-L)
- 0940-1334
- 1433-8491
- OpenAlex
- W2021077907
- Cited by
- 119
- References
- 4
- Citations by year
- 2026: 1 · 2025: 8 · 2024: 2 · 2023: 5 · 2022: 4 · 2021: 17 · 2020: 17 · 2019: 14 · 2018: 11 · 2017: 8 · 2016: 11 · 2015: 8 · 2014: 2 · 2013: 4 · 2012: 2
- FWCI
- 2.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Archives of Psychiatry and Clinical Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- anticholinergic agents, dementia risk, dementia prevention, Alzheimer's disease, cholinergic neurotransmission, neuroinflammation, primary care patients, cognitive impairment, drug safety
- MeSH terms
- Aged, Aged, 80 and over, Mental Disorders, Dementia, Female, Germany, Humans, Male, Risk Factors, Cohort Studies, Proportional Hazards Models, Survival Analysis, Cholinergic Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
